Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, ...

Some patients with this “cardiac variant” had proteinuria, but did not develop end-stage renal disease; they also differed ... sudden cardiac deaths are relatively frequent. Enzyme replacement therapy ...

However, the progress notes from the nursing chart remained in Chinese ... Supportive treatments such as continuous renal replacement therapy (CRRT), mechanical ventilation (MV), and vasopressor were ...

The following is a summary of “Risk factors for renal insufficiency and survival implications after radical nephrectomy and ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with significantly longer disease-free survival than placebo (24 months: 77% vs. 68%; ...

The global continuous renal replacement therapy market is set for significant expansion, with projections indicating a surge from USD 1,214.6 billion in 2023 to an estimated USD 2,771.6 billion by ...

First Full Characterization of Kidney Microbiome Unlocks Potential to Prevent Kidney Stones Dec. 11, 2024 — Researchers have found definitive proof of a kidney microbiome that influences renal ...

Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.

A clinical trial demonstrated that short-course, higher-dose vaginal brachytherapy for endometrial cancer is as effective as the standard, more frequent, lower-dose sessions.

In a randomized clinical trial, researchers from Huntsman Cancer Institute at the University of Utah (the U) have found that short-course, higher dose vaginal brachytherapy for endometrial cancer ...